

Gregory R Fulcher

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1812164/publications.pdf>

Version: 2024-02-01

41
papers

724
citations

623734

14
h-index

552781

26
g-index

43
all docs

43
docs citations

43
times ranked

1296
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of Insulin Degludec/Insulin Aspart and Biphasic Insulin Aspart 30 in Uncontrolled, Insulin-Treated Type 2 Diabetes: A Phase 3a, Randomized, Treat-to-Target Trial. <i>Diabetes Care</i> , 2014, 37, 2084-2090.	8.6	93
2	Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes – A systematic review. <i>Diabetes Research and Clinical Practice</i> , 2018, 140, 118-128.	2.8	71
3	The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys. <i>Journal of Medical Economics</i> , 2014, 17, 751-761.	2.1	47
4	Large-for-Gestational-Age Neonates in Type 1 Diabetes and Pregnancy: Contribution of Factors Beyond Hyperglycemia. <i>Diabetes Care</i> , 2018, 41, 1821-1828.	8.6	46
5	Amount and Type of Dietary Fat, Postprandial Glycemia, and Insulin Requirements in Type 1 Diabetes: A Randomized Within-Subject Trial. <i>Diabetes Care</i> , 2020, 43, 59-66.	8.6	39
6	Factors associated with patient activation in an Australian population with comorbid diabetes and chronic kidney disease: a cross-sectional study. <i>BMJ Open</i> , 2017, 7, e017695.	1.9	38
7	Long-Term Glycemic Variability and Vascular Complications in Type 2 Diabetes: Post Hoc Analysis of the FIELD Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e3638-e3649.	3.6	37
8	Challenges of diabetes management during the COVID-19 pandemic. <i>Medical Journal of Australia</i> , 2020, 213, 56.	1.7	34
9	Predictors of Health-Related Quality of Life in Patients with Co-Morbid Diabetes and Chronic Kidney Disease. <i>PLoS ONE</i> , 2016, 11, e0168491.	2.5	33
10	Self-management in patients with diabetes and chronic kidney disease is associated with incremental benefit in HRQOL. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 427-432.	2.3	24
11	Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus. <i>Therapeutic Advances in Chronic Disease</i> , 2015, 6, 375-388.	2.5	23
12	Treatment of chronic diabetic lower leg ulcers with activated protein C: a randomised placebo-controlled, double-blind pilot clinical trial. <i>International Wound Journal</i> , 2015, 12, 422-427.	2.9	22
13	Association Between Glycemic Variability, HbA1c, and Large-for-Gestational-Age Neonates in Women With Type 1 Diabetes. <i>Diabetes Care</i> , 2017, 40, e98-e100.	8.6	18
14	HbA1c variability in adults with type 1 diabetes on continuous subcutaneous insulin infusion (CSII) therapy compared to multiple daily injection (MDI) treatment. <i>BMJ Open</i> , 2019, 9, e033059.	1.9	16
15	Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2446-2456.	6.1	15
16	Use of metformin earlier in pregnancy predicts supplemental insulin therapy in women with gestational diabetes. <i>Diabetes Research and Clinical Practice</i> , 2016, 116, 96-99.	2.8	14
17	Activated protein C to heal pressure ulcers. <i>International Wound Journal</i> , 2016, 13, 986-991.	2.9	14
18	Identification of Patients With Diabetes Who Benefit Most From a Health Coaching Program in Chronic Disease Management, Sydney, Australia, 2013. <i>Preventing Chronic Disease</i> , 2017, 14, E21.	3.4	13

#	ARTICLE	IF	CITATIONS
19	Effects of canagliflozin on myocardial infarction: a <i>post hoc</i> analysis of the CANVAS programme and CREDENCE trial. <i>Cardiovascular Research</i> , 2022, 118, 1103-1114.	3.8	13
20	Routine glucose assessment in the emergency department for detecting unrecognised diabetes: a cluster randomised trial. <i>Medical Journal of Australia</i> , 2019, 211, 454-459.	1.7	12
21	The impact of an integrated diabetes and kidney service on patients, primary and specialist health professionals in Australia: A qualitative study. <i>PLoS ONE</i> , 2019, 14, e0219685.	2.5	11
22	Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1961-1975.	4.4	11
23	What happens when patients require intensification from basal insulin? A retrospective audit of clinical practice for the treatment of type 2 diabetes from four Australian centres. <i>Diabetes Research and Clinical Practice</i> , 2015, 108, 405-413.	2.8	10
24	Rationale and design of Short-Term EXenatide therapy in Acute ischaemic Stroke (STEXAS): a randomised, open-label, parallel-group study. <i>BMJ Open</i> , 2016, 6, e008203.	1.9	10
25	Outcomes for Women with Gestational Diabetes Treated with Metformin: A Retrospective, Case-Control Study. <i>Journal of Clinical Medicine</i> , 2018, 7, 50.	2.4	9
26	Patient-reported barriers and outcomes associated with poor glycaemic and blood pressure control in co-morbid diabetes and chronic kidney disease. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 63-68.	2.3	9
27	Suboptimal behaviour and knowledge regarding overnight glycaemia in adults with type 1 diabetes is common. <i>Internal Medicine Journal</i> , 2018, 48, 1080-1086.	0.8	6
28	Evaluation of the performance and outcomes for the first year of a diabetes rapid access clinic. <i>Medical Journal of Australia</i> , 2016, 205, 172-172.	1.7	5
29	Updated risk factors should be used to predict development of diabetes. <i>Journal of Diabetes and Its Complications</i> , 2017, 31, 859-863.	2.3	5
30	Patient reported barriers are associated with low physical and mental well-being in patients with co-morbid diabetes and chronic kidney disease. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 215.	2.4	5
31	Plasma protein C levels are directly associated with better outcomes in patients with severe burns. <i>Burns</i> , 2019, 45, 1659-1672.	1.9	4
32	ARISE—a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design. <i>Endocrine</i> , 2021, 74, 530-537.	2.3	4
33	Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries. <i>Advances in Therapy</i> , 2022, 39, 3735-3748.	2.9	3
34	Comment on Ooi and Wong. Twin Pregnancy With Gestational Diabetes Mellitus: A Double Whammy? <i>Diabetes Care</i> 2018;41:e15â€“e16. <i>Diabetes Care</i> , 2018, 41, e67-e67.	8.6	2
35	Utility of the Hospital Admission Risk Programme diabetes risk calculator in identifying patients with type 2 diabetes at risk of unplanned hospital presentations. <i>Internal Medicine Journal</i> , 2018, 48, 1198-1205.	0.8	1
36	Early protein C activation is reflective of burn injury severity and plays a critical role in inflammatory burden and patient outcomes. <i>Burns</i> , 2022, 48, 91-103.	1.9	1

#	ARTICLE	IF	CITATIONS
37	A co-designed integrated kidney and diabetes model of care improves mortality, glycaemic control and self-care. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1472-1481.	0.7	1
38	Continuous subcutaneous insulin infusion alters microRNA expression and glycaemic variability in children with type 1 diabetes. <i>Scientific Reports</i> , 2021, 11, 16656.	3.3	1
39	Women with type 2 diabetes in pregnancy remain a high-risk group. <i>Minerva Endocrinology</i> , 2018, 43, 224-225.	1.1	1
40	Prevention of cardiovascular disease: an evidence-based clinical aid. <i>Medical Journal of Australia</i> , 2004, 180, 197-198.	1.7	0
41	Epidermal Protein C Levels Correspond to Local Injury Severity and Increased Clinical Support in Burn Patients. <i>European Journal of Burn Care</i> , 2021, 2, 226-237.	0.8	0